2. Academic Validation
  3. Identification of novel PI3Kα inhibitors for colon cancer treatment via virtual screening, molecular dynamics simulation, and in vitro activity validation

Identification of novel PI3Kα inhibitors for colon cancer treatment via virtual screening, molecular dynamics simulation, and in vitro activity validation

  • Mol Divers. 2026 Jan 14. doi: 10.1007/s11030-025-11462-6.
Yu-Chen Wang # 1,  Xue Su # 2,  Xiang-Long Chen 2,  Xiu-Yun Shi 2,  Zhou-Lan Bai 3,  Hui Zhang 4 5
Affiliations

Affiliations

  • 1 Department of Third Oncology Surgery, General Hospital of Ningxia Medical University, Xingqing District, Yinchuan, 750004, People's Republic of China.
  • 2 College of Life Science, Northwest Normal University, Lanzhou, 730070, Gansu, People's Republic of China.
  • 3 Department of Third Oncology Surgery, General Hospital of Ningxia Medical University, Xingqing District, Yinchuan, 750004, People's Republic of China. [email protected].
  • 4 College of Life Science, Northwest Normal University, Lanzhou, 730070, Gansu, People's Republic of China. [email protected].
  • 5 State Key Laboratory of Biotherapy and Cancer Center, West ChinaHospital, West China Medical School, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China. [email protected].
  • # Contributed equally.
PMID: 41533018 DOI: 10.1007/s11030-025-11462-6
Keywords

In vitro assay; Molecular docking; Molecular dynamics; PI3Kα inhibitor.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-181150
    PI3Kα Inhibitor